ST PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 101,800 KRW | +5.93% |
|
+11.62% | +50.15% |
| 2023 | ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2021 | ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility | CI |
ETFs positioned on ST Pharm Co.,Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 7 M€ | +6.58% | - | |
| 0.00% | 112 M€ | +5.41% | - | |
| 0.00% | 34 M€ | +3.87% | - |
STPharm Co.,Ltd. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The Company's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
101,800
KRW
Average target price
105,000
KRW
Spread / Average Target
+3.14%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +50.15% | 1.42B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- A237690 Stock
- Funds and ETFs ST Pharm Co.,Ltd.
